137 related articles for article (PubMed ID: 27468630)
1. Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.
Papamichael D; Renfro LA; Matthaiou C; Yothers G; Saltz L; Guthrie KA; Van Cutsem E; Schmoll HJ; Labianca R; André T; O'Connell M; Alberts SR; Haller DG; Kountourakis P; Sargent DJ;
J Geriatr Oncol; 2016 Nov; 7(6):422-429. PubMed ID: 27468630
[TBL] [Abstract][Full Text] [Related]
2. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
[TBL] [Abstract][Full Text] [Related]
3. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B
Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
5. Young age influences treatment but not outcome of colon cancer.
Quah HM; Joseph R; Schrag D; Shia J; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
Ann Surg Oncol; 2007 Oct; 14(10):2759-65. PubMed ID: 17593332
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
[TBL] [Abstract][Full Text] [Related]
7. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.
de Gramont A; Hubbard J; Shi Q; O'Connell MJ; Buyse M; Benedetti J; Bot B; O'Callaghan C; Yothers G; Goldberg RM; Blanke CD; Benson A; Deng Q; Alberts SR; Andre T; Wolmark N; Grothey A; Sargent D
J Clin Oncol; 2010 Jan; 28(3):460-5. PubMed ID: 20008641
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
[TBL] [Abstract][Full Text] [Related]
9. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set.
Hubbard J; Thomas DM; Yothers G; Green E; Blanke C; O'Connell MJ; Labianca R; Shi Q; Bleyer A; de Gramont A; Sargent D
J Clin Oncol; 2012 Jul; 30(19):2334-9. PubMed ID: 22614981
[TBL] [Abstract][Full Text] [Related]
10. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
11. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
13. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
14. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.
Yokota M; Kojima M; Nomura S; Nishizawa Y; Kobayashi A; Ito M; Ochiai A; Saito N
Dis Colon Rectum; 2014 Jul; 57(7):830-8. PubMed ID: 24901683
[TBL] [Abstract][Full Text] [Related]
16. Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).
Cheng E; Ou FS; Ma C; Spiegelman D; Zhang S; Zhou X; Bainter TM; Saltz LB; Niedzwiecki D; Mayer RJ; Whittom R; Hantel A; Benson A; Atienza D; Messino M; Kindler H; Giovannucci EL; Van Blarigan EL; Brown JC; Ng K; Gross CP; Meyerhardt JA; Fuchs CS
J Clin Oncol; 2022 Mar; 40(7):740-751. PubMed ID: 34995084
[TBL] [Abstract][Full Text] [Related]
17. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
Sargent DJ; Patiyil S; Yothers G; Haller DG; Gray R; Benedetti J; Buyse M; Labianca R; Seitz JF; O'Callaghan CJ; Francini G; Grothey A; O'Connell M; Catalano PJ; Kerr D; Green E; Wieand HS; Goldberg RM; de Gramont A;
J Clin Oncol; 2007 Oct; 25(29):4569-74. PubMed ID: 17876008
[TBL] [Abstract][Full Text] [Related]
18. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.
Sinicrope FA; Foster NR; Yothers G; Benson A; Seitz JF; Labianca R; Goldberg RM; Degramont A; O'Connell MJ; Sargent DJ;
Cancer; 2013 Apr; 119(8):1528-36. PubMed ID: 23310947
[TBL] [Abstract][Full Text] [Related]
19. Predicting Individualized Postoperative Survival for Stage II/III Colon Cancer Using a Mobile Application Derived from the National Cancer Data Base.
Gabriel E; Attwood K; Thirunavukarasu P; Al-Sukhni E; Boland P; Nurkin S
J Am Coll Surg; 2016 Mar; 222(3):232-44. PubMed ID: 26922599
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant chemotherapy for colon cancer].
Dahl O
Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3094-6. PubMed ID: 18049502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
